Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE)

Bondeson, Jan and Maini, R. N. 2001. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). International Journal of Clinical Practice 55 (3) , pp. 211-216.

Full text not available from this repository.

Abstract

Therapeutic strategies that aim to neutralise the important pro-inflammatory cytokine tumour necrosis factor alpha (TNF alpha) have gained considerable prominence in the therapy of chronic inflammatory diseases, notably rheumatoid arthritis and Crohn's disease. This drug focus review will concentrate on the antitumour necrosis factor antibody infliximab (Remicade), which has been approved for the treatment of rheumatoid arthritis and Crohn's disease in both the US and Europe. In addition, infliximab is under investigation for several other indications, mainly inflammatory rheumatic diseases. Clinical trials have been persuasive that infliximab is both safe and effective, and it has been proven to be far superior to the conventional drug therapy in both rheumatoid arthritis and Crohn's disease. Remarkably, infliximab in combination with methotrexate controls both the inflammatory joint symptoms and the progression of joint damage, which renders it a very attractive therapeutic option in moderate to severe, therapy-resistant rheumatoid arthritis.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Uncontrolled Keywords: Antibodies, Monoclonal/therapeutic use, Antirheumatic Agents/therapeutic use, Arthritis, Juvenile/drug therapy, Arthritis, Psoriatic/drug therapy, Arthritis, Rheumatoid/drug therapy, Crohn Disease/drug therapy, Humans, Tumor Necrosis Factor-alpha/drug effects
Publisher: Wiley-Blackwell
ISSN: 1368-5031
Last Modified: 30 Jun 2017 03:25
URI: http://orca-mwe.cf.ac.uk/id/eprint/57176

Citation Data

Cited 42 times in Google Scholar. View in Google Scholar

Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item